Fulgent Genetics Reports First Quarter 2017 Financial Results
May 08, 2017 20:07 pm UTC| Business
Revenue grows 54% year over year to $5.3 MillionGAAP Income of $0.2 Million, or $0.01 per ShareNon-GAAP Income of $0.6 Million, or $0.03 per ShareAdjusted EBITDA of $1.2 MillionCash Flow from Operating Activities of $0.7...
Fulgent Genetics Reports First Quarter 2017 Financial Results
May 08, 2017 20:07 pm UTC| Business
Revenue grows 54% year over year to $5.3 MillionGAAP Income of $0.2 Million, or $0.01 per ShareNon-GAAP Income of $0.6 Million, or $0.03 per ShareAdjusted EBITDA of $1.2 MillionCash Flow from Operating Activities of $0.7...
The Bon-Ton Stores, Inc. Announces Management Reorganization
May 08, 2017 20:07 pm UTC| Business
YORK, Pa., May 08, 2017 -- The Bon-Ton Stores, Inc. (NASDAQ:BONT) announced today that Kathryn Bufano, President and Chief Executive Officer, has resigned from the Company effective August 25, 2017, upon expiration of...
The Bon-Ton Stores, Inc. Announces Management Reorganization
May 08, 2017 20:07 pm UTC| Business
YORK, Pa., May 08, 2017 -- The Bon-Ton Stores, Inc. (NASDAQ:BONT) announced today that Kathryn Bufano, President and Chief Executive Officer, has resigned from the Company effective August 25, 2017, upon expiration of...
The Bon-Ton Stores, Inc. Announces Management Reorganization
May 08, 2017 20:07 pm UTC| Business
YORK, Pa., May 08, 2017 -- The Bon-Ton Stores, Inc. (NASDAQ:BONT) announced today that Kathryn Bufano, President and Chief Executive Officer, has resigned from the Company effective August 25, 2017, upon expiration of...
Kura Oncology to Report First Quarter 2017 Financial Results
May 08, 2017 20:07 pm UTC| Business
LA JOLLA, Calif., May 08, 2017 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first...
Kura Oncology to Report First Quarter 2017 Financial Results
May 08, 2017 20:07 pm UTC| Business
LA JOLLA, Calif., May 08, 2017 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first...